Operating Activities

(8) Segment Reporting

Accounting and measurement policies
Segment reporting

The Group’s business activities are broken down into the three operational business sectors of Life Science, Healthcare and Electronics, as well as the central Group functions. This segment structure reflects the internal organizational and reporting structure. The Life Science business sector encompasses business with tools, chemicals and equipment for academic labs, biotech and pharmaceutical manufacturers, as well as the industrial sector. The Healthcare business sector discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals. The Electronics business sector supplies materials for the semiconductor and display industries and, until July 31, 2025, for surface design (see Note (6) Acquisitions and divestments). The three business sectors differ in terms of their products and services, their customers, their sales structures and processes, and the regulatory environment in which they operate. The activities that are bundled in each individual business sector are extremely similar in terms of these criteria. The central Group functions also encompass service activities and other Group functions that are not allocated to any of the business sectors. Resource allocation and the assessment of business development are performed at the level of the business sectors by the Executive Board of Merck KGaA, Darmstadt, Germany, as the chief operating decision-maker.

In addition to the direct activities of the central Group functions, “Corporate and Other” includes income and expenses, assets and liabilities, as well as cash flows that cannot be allocated to the reportable segments as they are managed at Group level in central Group functions. This relates in particular to expenses and income for the foreign currency hedging of transactions in operating business, financial expenses and financial income, which include interest expenses and interest income as well as income tax expenses and income. Financial liabilities, pension provisions as well as income tax assets and liabilities are also allocated to “Corporate and Other”. Moreover, the column serves as the reconciliation to the Group figures.

Apart from net sales, the success of a segment is mainly determined by EBITDA pre (segment result). EBITDA pre is a key figure that is not defined by IFRS Accounting Standards. However, it represents the most important variable used to steer the Group. To permit a better understanding of operational performance, EBITDA pre excludes depreciation and amortization, impairment losses and reversals of impairment losses in addition to specific adjustments presented below.

The segment data is derived from the financial information, which is based on the IFRS Accounting Standards applied in the Consolidated Financial Statements. Transfer prices for intragroup net sales were determined on an arm’s-length basis for all of the business sectors. Fixed assets are allocated to the segments based on the degree of utilization. Depreciation expenses are allocated on the same basis. Fixed assets are always recognized by the buyer at the amortized Group cost following intragroup transactions. Services performed by the Group functions are allocated on the basis of planning data. Any deviations in the actual costs incurred are not allocated to the reportable operating segments but continue to be recognized in the “Corporate and Other” column.

Information by business sector – 2025

€ million

 

Life Science

 

Healthcare

 

Electronics

 

Total of reportable operating segments

 

Corporate and Other

 

Group

Net sales1

 

8,980

 

8,607

 

3,515

 

21,102

 

 

21,102

Intersegment sales

 

111

 

 

 

111

 

-111

 

Cost of sales

 

-4,225

 

-2,368

 

-2,162

 

-8,755

 

 

-8,756

Marketing and selling expenses

 

-2,199

 

-1,832

 

-519

 

-4,550

 

-12

 

-4,562

Administration expenses

 

-449

 

-355

 

-151

 

-956

 

-482

 

-1,437

Research and development costs

 

-401

 

-1,661

 

-291

 

-2,353

 

-62

 

-2,415

Operating result (EBIT)2

 

1,467

 

2,165

 

381

 

4,013

 

-413

 

3,601

Depreciation

 

857

 

453

 

448

 

1,758

 

122

 

1,880

Impairment losses3

 

99

 

246

 

73

 

418

 

 

418

Reversals of impairment losses

 

 

 

 

 

 

EBITDA4

 

2,423

 

2,864

 

903

 

6,190

 

-291

 

5,899

Adjustments2

 

162

 

216

 

-70

 

307

 

-97

 

210

EBITDA pre (segment result)2

 

2,585

 

3,080

 

833

 

6,497

 

-388

 

6,109

EBITDA pre margin (in % of net sales)2

 

28.8%

 

35.8%

 

23.7%

 

 

 

28.9%

Assets by business sector

 

23,207

 

11,722

 

9,117

 

44,046

 

7,482

 

51,527

Liabilities by business sector

 

-1,809

 

-2,876

 

-592

 

-5,277

 

-17,591

 

-22,867

Investments in property, plant and equipment5

 

745

 

276

 

450

 

1,472

 

113

 

1,585

Investments in intangible assets5

 

54

 

229

 

53

 

336

 

37

 

373

Non-cash changes in provisions5,6

 

117

 

124

 

133

 

374

 

43

 

417

1

Excluding intersegment sales.

2

Not defined by IFRS Accounting Standards.

3

Without impairments on financial assets and inventories.

4

Not defined by IFRS Accounting Standards; EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses.

5

According to the Consolidated Cash Flow Statement.

6

Excluding provisions for pensions and other post-employment benefits.

Information by business sector – 2024

€ million

 

Life Science

 

Healthcare

 

Electronics

 

Total of reportable operating segments

 

Corporate and Other

 

Group

Net sales1

 

8,916

 

8,455

 

3,785

 

21,156

 

 

21,156

Intersegment sales

 

91

 

 

 

91

 

-91

 

Cost of sales

 

-4,150

 

-2,201

 

-2,319

 

-8,670

 

-1

 

-8,671

Marketing and selling expenses

 

-2,238

 

-1,713

 

-568

 

-4,519

 

-18

 

-4,536

Administration expenses

 

-441

 

-313

 

-166

 

-919

 

-450

 

-1,370

Research and development costs

 

-388

 

-1,503

 

-297

 

-2,187

 

-92

 

-2,279

Operating result (EBIT)2

 

1,507

 

2,481

 

360

 

4,347

 

-702

 

3,645

Depreciation

 

862

 

331

 

498

 

1,690

 

116

 

1,806

Impairment losses3

 

87

 

209

 

29

 

325

 

3

 

328

Reversals of impairment losses

 

 

 

 

 

 

EBITDA4

 

2,455

 

3,021

 

887

 

6,362

 

-584

 

5,779

Adjustments2

 

134

 

-26

 

83

 

191

 

102

 

293

EBITDA pre (segment result)2

 

2,589

 

2,995

 

970

 

6,553

 

-482

 

6,072

EBITDA pre margin (in % of net sales)2

 

29.0%

 

35.4%

 

25.6%

 

 

 

28.7%

Assets by business sector5

 

25,220

 

8,620

 

10,764

 

44,604

 

6,992

 

51,596

Liabilities by business sector5

 

-1,912

 

-2,858

 

-670

 

-5,439

 

-16,168

 

-21,607

Investments in property, plant and equipment6

 

858

 

302

 

396

 

1,556

 

146

 

1,702

Investments in intangible assets6

 

44

 

348

 

43

 

435

 

47

 

482

Non-cash changes in provisions6,7

 

95

 

150

 

95

 

339

 

42

 

381

1

Excluding intersegment sales.

2

Not defined by IFRS Accounting Standards.

3

Without impairments on financial assets and inventories.

4

Not defined by IFRS Accounting Standards; EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses.

5

Previous-year figures have been adjusted owing to the finalization of the purchase price allocation in connection with the acquisitions of Mirus Bio LLC, USA, Unity-SC SAS, France, as well as Hub Organoids Holding B.V., Netherlands (see Note (6) Acquisitions and divestments).

6

According to the Consolidated Cash Flow Statement.

7

Excluding provisions for pensions and other post-employment benefits.

Information by country and region – 2025

€ million

 

Europe

 

thereof: Germany

 

thereof: Switzerland

 

North America

 

thereof: USA

 

Asia-Pacific

 

thereof: China

 

Latin America

 

Middle East and Africa

 

Group

Net sales by customer location1

 

6,417

 

1,011

 

401

 

5,517

 

5,238

 

6,936

 

2,888

 

1,447

 

785

 

21,102

Net sales by company location1

 

6,758

 

1,459

 

611

 

5,693

 

5,433

 

6,605

 

2,734

 

1,397

 

650

 

21,102

Goodwill and other intangible assets2

 

4,903

 

1,488

 

1,684

 

20,404

 

20,395

 

288

 

35

 

1

 

 

25,596

Property, plant and equipment

 

5,340

 

2,533

 

1,035

 

2,811

 

2,808

 

1,521

 

387

 

197

 

71

 

9,940

Research and development costs

 

-1,901

 

-1,167

 

-561

 

-426

 

-426

 

-57

 

-27

 

-20

 

-10

 

-2,415

Number of employees

 

27,444

 

12,540

 

2,678

 

14,583

 

14,383

 

15,802

 

4,359

 

3,467

 

1,165

 

62,461

1

Excluding intersegment sales.

2

Goodwill and other intangible assets are allocated by currency area.

Information by country and region – 2024

€ million

 

Europe

 

thereof: Germany

 

thereof: Switzerland

 

North America

 

thereof: USA

 

Asia-Pacific

 

thereof: China4

 

Latin America

 

Middle East and Africa

 

Group

Net sales by customer location1

 

6,171

 

1,002

 

389

 

5,710

 

5,426

 

7,017

 

2,900

 

1,477

 

781

 

21,156

Net sales by company location1

 

6,506

 

1,411

 

594

 

5,915

 

5,652

 

6,719

 

2,781

 

1,427

 

590

 

21,156

Goodwill and other intangible assets2,3

 

5,079

 

1,539

 

1,772

 

19,998

 

19,987

 

380

 

45

 

1

 

 

25,458

Property, plant and equipment

 

5,182

 

2,439

 

1,070

 

3,083

 

3,078

 

1,489

 

478

 

201

 

71

 

10,025

Research and development costs

 

-1,835

 

-1,062

 

-619

 

-355

 

-353

 

-58

 

-27

 

-21

 

-10

 

-2,279

Number of employees

 

28,138

 

13,236

 

2,632

 

14,187

 

13,976

 

15,593

 

4,421

 

3,502

 

1,137

 

62,557

1

Excluding intersegment sales.

2

Goodwill and other intangible assets are allocated by currency area.

3

Previous-year figures have been adjusted owing to the finalization of the purchase price allocation in connection with the acquisitions of Mirus Bio LLC, USA, Unity-SC SAS, France, as well as Hub Organoids Holding B.V., Netherlands (see Note (6) Acquisitions and divestments).

4

Previous-year figures have been adjusted because, starting with fiscal 2025, the values attributable to Hong Kong will be presented as part of China.

No single customer accounted for more than 10% of the Group’s total net sales in fiscal 2025 or 2024.

The following table presents the reconciliation of segment results of all operating businesses to the profit before income tax of the Group:

Reconciliation of segment results to the profit before income tax

€ million

 

2025

 

2024

EBITDA pre of the operating businesses1

 

6,497

 

6,553

Corporate and Other

 

-388

 

-482

EBITDA pre of the Group1

 

6,109

 

6,072

Depreciation/amortization/impairment losses/reversals of impairment losses

 

-2,298

 

-2,134

Adjustments1

 

-210

 

-293

Operating result (EBIT)1

 

3,601

 

3,645

Financial income and expenses

 

-293

 

-108

Profit before income tax

 

3,308

 

3,536

1

Not defined by IFRS Accounting Standards. Please refer to the following table for the components of the adjustments.

The adjustments comprised the following:

Adjustments in the operating result

€ million

 

2025

 

2024

Restructuring expenses

 

-174

 

-144

Integration expenses/IT expenses

 

-193

 

-103

Gains (+)/losses (-) on the divestment of businesses

 

88

 

46

Acquisition-related adjustments

 

-44

 

-26

Other adjustments

 

113

 

-68

Adjustments before impairment losses/reversals of impairment losses1

 

-210

 

-293

Impairment losses2

 

-369

 

-277

Reversals of impairment losses

 

 

Adjustments (total)1

 

-579

 

-570

1

Not defined by IFRS Accounting Standards.

2

Without impairments on financial assets and inventories.

In fiscal 2025, restructuring expenses primarily related to various programs for improving efficiency in the three business sectors. The largest share was attributable to the Healthcare business sector with € 65 million and Life Science with € 64 million. In the previous year, the largest restructuring expenses were in connection with an efficiency program in the Life Science business sector amounting to € 46 million and a program for further improving processes and aligning the enabling functions more closely with the businesses at € 41 million (2025: € 15 million) (see Note (27) Other provisions).

Integration and IT expenses in fiscal 2025 mainly related to the integration of SpringWorks Therapeutics, Inc., United States, acquired on July 1, 2025 (€ 99 million) (see Note (6) Acquisitions and divestments), as well as to costs for the further development of ERP systems.

Gains on the divestment of businesses were due in particular to the divestiture of the Surface Solutions business unit to Global New Material International Holdings Ltd., Cayman Islands, on July 31, 2025; see Note (6) Acquisitions and divestments. Furthermore, as in the previous year, income was generated in connection with the biosimilars business that was sold to a subsidiary of Fresenius SE & Co. KGaA, Bad Homburg vor der Höhe, Germany, in fiscal 2017; see Note (43) Information on fair value measurement.

Other adjustments include the losses on the net position of monetary assets and liabilities resulting from hyperinflationary accounting in Argentina and Turkey, which are reported in other operating expenses (see Note (2) Reporting principles and Note (14) Other operating expenses). Furthermore, currency translation differences realized here are included due to an absolute reduction in the share in a foreign operation with the corresponding reclassification of the pro rata cumulative currency translation difference (see Note (13) Other operating income).

Impairment losses considered as adjustments amounted to € 174 million (2024: € 142 million) related to intangible assets in the Healthcare business sector (see Note (19) Other intangible assets) and € 166 million (2024: € 83 million) to property, plant and equipment, primarily in the Life Science business sector.

The adjustments are reported in the Consolidated Income Statement as part of the respective functional costs and allocated to them as follows:

2025

€ million

 

thereof: cost of sales

 

thereof: marketing and selling expenses

 

thereof: administration expenses

 

thereof: research and development expenses

 

thereof: others

 

Total

Restructuring expenses

 

-83

 

-39

 

-28

 

3

 

-28

 

-174

Integration expenses/IT expenses

 

-1

 

-32

 

-104

 

-36

 

-20

 

-193

Gains (+)/losses (-) on the divestment of businesses

 

-30

 

 

 

 

118

 

88

Acquisition-related adjustments

 

 

 

-1

 

 

-43

 

-44

Other adjustments

 

 

 

 

 

113

 

113

Adjustments before impairment losses/reversals of impairment losses1

 

-113

 

-71

 

-132

 

-33

 

140

 

-210

Impairment losses2

 

 

 

 

 

-369

 

-369

Reversals of impairment losses

 

 

 

 

 

 

Adjustments in the operating result (total)1

 

-113

 

-71

 

-132

 

-33

 

-230

 

-579

1

Not defined by IFRS Accounting Standards.

2

Without impairments on financial assets and inventories.

2024

€ million

 

thereof: cost of sales

 

thereof: marketing and selling expenses

 

thereof: administration expenses

 

thereof: research and development expenses

 

thereof: others

 

Total

Restructuring expenses

 

-39

 

-27

 

-58

 

-10

 

-10

 

-144

Integration expenses/IT expenses

 

-2

 

 

-90

 

-1

 

-10

 

-103

Gains (+)/losses (-) on the divestment of businesses

 

 

-3

 

-6

 

 

55

 

46

Acquisition-related adjustments

 

 

 

 

 

-25

 

-26

Other adjustments

 

 

 

 

 

-68

 

-68

Adjustments before impairment losses/reversals of impairment losses1

 

-41

 

-30

 

-154

 

-11

 

-57

 

-293

Impairment losses2

 

 

 

 

 

-277

 

-277

Reversals of impairment losses

 

 

 

 

 

 

Adjustments in the operating result (total)1

 

-41

 

-30

 

-154

 

-11

 

-335

 

-570

1

Not defined by IFRS Accounting Standards.

2

Without impairments on financial assets.

Share this page: